Ebola is unlikely to become a profitable endeavor for Western pharmaceutical companies, “affecting primarily the poor in Africa with demand for drugs relatively modest,” according to John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries.
Always Be a Step Ahead
Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.
Subscribe to AMI's Insights Newsletter Today.